Related Experiment Video
Updated: Aug 18, 2026
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
Subcortical vascular dementia: survey of treatment patterns and research considerations
F J Molnar1, M Man-Son-Hing, P St John
1Division of Geriatric Medicine, University of Ottawa, Ontario, Canada.
Background:
Since few studies have examined the effectiveness of therapies for subcortical vascular dementia, treatment guidelines are not available. Current patterns in the treatment of such dementias have not been studied.
Objective:
To determine the practice patterns of Canadian specialists for the treatment of subcortical vascular dementia, and to survey their opinions regarding issues which are important in the design of a randomized controlled trial (RCT) in this field.
Design:
National survey of all specialists certified in Neurology or Geriatric Medicine.
Results:
Of responding physicians (78%) prescribed antithrombotic therapy for patients with vascular dementia. Most begin treatment with aspirin 325 mg daily (64%). The next three most common initial treatments were; no pharmacotherapy (12%), aspirin 650 mg daily (11%), and aspirin 1300 mg daily (11%). If the dementia continued to progress despite initial therapy, the treatment options were more varied. Most specialists (69%) believed that an RCT to assess the efficacy of aspirin in vascular dementia is warranted. The majority (69%) also felt that serial neuroimaging would be required for participants in such a trial, with magnetic resonance imaging being cited most frequently (41%). The majority of specialists considered three years as the minimum duration for such a trial.
Conclusions:
Specialist physician practice patterns vary significantly for the treatment of patients with subcortical vascular dementia. Most physicians believe that an RCT testing the efficacy of aspirin in this condition is required. However, before such a trial can be conducted, many methodological difficulties need to be addressed.
Insights
Canadian specialists vary in treating subcortical vascular dementia. Most advocate for randomized controlled trials (RCTs) on aspirin but face methodological challenges before initiating such studies.
Area of Science:
- Neurology
- Geriatric Medicine
- Vascular Dementia Research
Background:
- Limited research exists on effective therapies for subcortical vascular dementia, leading to a lack of established treatment guidelines.
- Current treatment practices for subcortical vascular dementia have not been systematically studied.
Purpose of the Study:
- To investigate the treatment practices of Canadian specialists for subcortical vascular dementia.
- To gather specialist opinions on key considerations for designing a randomized controlled trial (RCT) in this area.
Main Methods:
- A national survey was conducted among specialists certified in Neurology or Geriatric Medicine.
- The survey aimed to determine current treatment patterns and expert opinions on future research.
Main Results:
- 78% of responding physicians prescribed antithrombotic therapy for vascular dementia, commonly starting with aspirin 325 mg daily.
- Treatment options varied if dementia progressed; however, most specialists (69%) supported an RCT for aspirin efficacy.
- A majority favored serial neuroimaging (MRI) and a minimum trial duration of three years for such studies.
Conclusions:
- Significant variation exists in specialist treatment approaches for subcortical vascular dementia.
- Most specialists agree on the need for an RCT to evaluate aspirin's efficacy.
- Methodological challenges must be resolved before a definitive RCT can be conducted.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:30Dementia
The progression of dementia is generally gradual.
01:22Dementia l: Introduction